Viking Therapeutics, Inc. (NASDAQ:VKTX) Files An 8-K Results of Operations and Financial Condition

Viking Therapeutics, Inc. (NASDAQ:VKTX) Files An 8-K Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition.

On May 10, 2017, we issued a press release reporting our
financial results for the first quarter ended March 31, 2017 and
providing a corporate update. The full text of the press release
is furnished as exhibit 99.1 to this Current Report on Form 8-K
and incorporated herein by reference.

In accordance with General Instructions B.2 of Form 8-K, the
information in Item 2.02 of this Current Report on Form 8-K shall
not be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liability of that section, and shall not be
incorporated by reference into any registration statement or
other document filed under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No

Description

99.1

Press release issued May 10, 2017, reporting financial
results for the first quarter ended March 31, 2017 and
providing a corporate update.


About Viking Therapeutics, Inc. (NASDAQ:VKTX)

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Recent Trading Information

Viking Therapeutics, Inc. (NASDAQ:VKTX) closed its last trading session 00.00 at 1.38 with 28,917 shares trading hands.

An ad to help with our costs